Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | NPC1 | O15118 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PTPRA | P18433 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20509994 | 0.85 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9ALMNAPARP10 | |
| SCHEMBL6562475 | 0.83 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ALMNAPARP10 | |
| SCHEMBL11377704 | 0.83 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9ALMNAPARP10 | |
| SCHEMBL26617154 | 0.82 | NPC1 (0.56) | SMN1; SMN2NPC1RAB9ALMNAPARP10 | |
| SCHEMBL533732 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9ALMNAPARP10 | |
| SCHEMBL17424653 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9ALMNAPARP10 | |
| SCHEMBL7442406 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9ALMNAPARP10 | |
| SCHEMBL6223872 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9ALMNAPARP10 | |
| SCHEMBL11234908 | 0.81 | NPC1 (0.59) | SMN1; SMN2NPC1RAB9ALMNAPARP10 | |
| SCHEMBL15040865 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9ALMNAPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE40558-E1 | Therapeutic uses of di-aryl acid derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-28 | — | — | US | claimed |
| US-6635655-B1 | Agonists or antagonists of peroxisome proliferator-activated receptors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-10-21 | — | — | US | claimed |
| EP-4340887-A1 | BIFUNCTIONAL PROTAC-TYPE COMPOUNDS TARGETING PXR, METHOD FOR PREPARING SAME, AND THERAPEUTIC USE THEREOF | Centre National de la Recherche Scientifique (FR) | 2024-03-27 | — | — | EP | disclosed |
| EP-3091053-B1 | OPTICAL FLUORESCENT IMAGING USING CYANINE DYES | LI COR INC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10787576-B2 | Method for the preparation of a coating comprising oligomeric alkynes | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) EPFL-TTO (CH) | 2020-09-29 | — | — | US | disclosed |
| EP-3599239-A1 | METAL ORGANIC FRAMEWORKS AND METHODS FOR USING THEREOF | Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO (CH) | 2020-01-29 | — | — | EP | disclosed |
| US-20190233409-A1 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2019-08-01 | — | — | US | disclosed |
| US-20190048202-A1 | METHOD FOR THE PREPARATION OF A COATING COMPRISING OLIGOMERIC ALKYNES | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) EPFL-TTO (CH) | 2019-02-14 | — | — | US | disclosed |
| US-20180171152-A1 | METHOD FOR THE PREPARATION OF A COATING | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) EPFL-TTO (CH) | 2018-06-21 | — | — | US | disclosed |
| EP-3303482-A1 | METHOD FOR THE PREPARATION OF A COATING | Ecole Polytechnique Fédérale de Lausanne (EPFL) EPFL-TTO (CH) | 2018-04-11 | — | — | EP | disclosed |
| EP-2808325-B1 | Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for the production and use thereof | ALLA CHEM LLC (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-1999031491-A1 | METHOD AND REAGENTS FOR THE QUANTIFICATION OF SOLID-PHASE REACTIONS USING FLUORINE NMR | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| WO-1999025752-A1 | FUNCTIONALIZED RESIN FOR THE SYNTHESIS OF AMIDES AND PEPTIDES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-05-27 | — | — | WO | disclosed |
| WO-1999020275-A1 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| EP-0894088-A1 | SUBSTITUTED SULFONIC ACID N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLAMIDE COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-02-03 | — | — | EP | disclosed |
| EP-0853618-A1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-07-22 | — | — | EP | disclosed |
| WO-1998025611-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-06-18 | — | — | WO | disclosed |
| WO-1998024784-A1 | SUBSTITUTED SULFONIC ACID N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLAMIDE COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| US-5731315-A | Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-03-24 | — | — | US | disclosed |
| WO-1996040679-A1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233409-A1 | SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF | ADORA3, HTR3C, TRPV3 | SMN1; SMN2 4246/4885NPC1 2185/4885RAB9A 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.